FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979222313> ?p ?o ?g. }

• W2979222313 endingPage "115" @default.
• W2979222313 startingPage "108" @default.
• W2979222313 abstract "Purpose In the multicenter, phase 3, HYpofractionated irradiation for PROstate cancer trial, hypofractionated (HF) radiation therapy was compared with conventionally fractionated (CF) radiation therapy. In previous reports, we could not demonstrate the postulated superiority of hypofractionation in terms of relapse-free survival at 5 years. The frequent use of long-term androgen deprivation therapy might have had substantial effects on relapse-free survival. In the current analysis, we provide updated 7-year relapse-free survival outcomes. Methods and Materials We enrolled patients with intermediate- to high-risk T1b-T4NX-N0MX-M0 localized prostate cancer. Patients were randomly assigned (1:1) to either HF (64.6 Gy in 19 fractions) or CF (78.0 Gy in 39 fractions) radiation therapy. Based on an estimated α/β ratio for prostate cancer of 1.5 Gy, the EQD2 was 90.4 Gy for HF versus 78.0 Gy for CF radiation therapy. The primary endpoint of the present analysis is relapse-free survival at 7 years. Results A total of 820 patients were enrolled, of whom 804 were assessable for the current evaluation (407 HF versus 397 CF). Median follow-up was 89 months (interquartile range, 83-99). Concomitant androgen deprivation therapy was prescribed for 537 (67%) of 804 patients for a median duration of 32 months (interquartile range, 10-44). Treatment failure at 7 years was reported in 220 (27.4%) of 804 patients, 107 (26.3%) in HF versus 113 (28.5%) in CF radiation therapy. Seven-year relapse-free survival was 71.7% (95% confidence interval [CI], 66.4-76.4) for HF versus 67.6% (95% CI, 62.0-72.5) for CF (P = .52). Overall survival was 80.8% (95% CI, 76.5-84.4) in HF versus 77.6% (95% CI, 73.0-81.5) in CF radiation therapy (P = .17). Conclusions The current results of 7-year relapse-free survival confirmed our previous findings that the hypothesized dose escalation in the HF arm did not translate to superior tumor control compared with the CF arm. In the multicenter, phase 3, HYpofractionated irradiation for PROstate cancer trial, hypofractionated (HF) radiation therapy was compared with conventionally fractionated (CF) radiation therapy. In previous reports, we could not demonstrate the postulated superiority of hypofractionation in terms of relapse-free survival at 5 years. The frequent use of long-term androgen deprivation therapy might have had substantial effects on relapse-free survival. In the current analysis, we provide updated 7-year relapse-free survival outcomes. We enrolled patients with intermediate- to high-risk T1b-T4NX-N0MX-M0 localized prostate cancer. Patients were randomly assigned (1:1) to either HF (64.6 Gy in 19 fractions) or CF (78.0 Gy in 39 fractions) radiation therapy. Based on an estimated α/β ratio for prostate cancer of 1.5 Gy, the EQD2 was 90.4 Gy for HF versus 78.0 Gy for CF radiation therapy. The primary endpoint of the present analysis is relapse-free survival at 7 years. A total of 820 patients were enrolled, of whom 804 were assessable for the current evaluation (407 HF versus 397 CF). Median follow-up was 89 months (interquartile range, 83-99). Concomitant androgen deprivation therapy was prescribed for 537 (67%) of 804 patients for a median duration of 32 months (interquartile range, 10-44). Treatment failure at 7 years was reported in 220 (27.4%) of 804 patients, 107 (26.3%) in HF versus 113 (28.5%) in CF radiation therapy. Seven-year relapse-free survival was 71.7% (95% confidence interval [CI], 66.4-76.4) for HF versus 67.6% (95% CI, 62.0-72.5) for CF (P = .52). Overall survival was 80.8% (95% CI, 76.5-84.4) in HF versus 77.6% (95% CI, 73.0-81.5) in CF radiation therapy (P = .17). The current results of 7-year relapse-free survival confirmed our previous findings that the hypothesized dose escalation in the HF arm did not translate to superior tumor control compared with the CF arm." @default.
• W2979222313 created "2019-10-10" @default.
• W2979222313 creator A5016754892 @default.
• W2979222313 creator A5022999007 @default.
• W2979222313 creator A5041705953 @default.
• W2979222313 creator A5042610590 @default.
• W2979222313 creator A5045236213 @default.
• W2979222313 creator A5068826699 @default.
• W2979222313 date "2020-01-01" @default.
• W2979222313 modified "2023-10-18" @default.
• W2979222313 title "Hyprofractionated Versus Conventionally Fractionated Radiation Therapy for Patients with Intermediate- or High-Risk, Localized, Prostate Cancer: 7-Year Outcomes From the Randomized, Multicenter, Open-Label, Phase 3 HYPRO Trial" @default.
• W2979222313 cites W1988308740 @default.
• W2979222313 cites W1990510898 @default.
• W2979222313 cites W1992743783 @default.
• W2979222313 cites W2004080729 @default.
• W2979222313 cites W2014239903 @default.
• W2979222313 cites W2033645471 @default.
• W2979222313 cites W2033942571 @default.
• W2979222313 cites W2053852532 @default.
• W2979222313 cites W2097532477 @default.
• W2979222313 cites W2100100699 @default.
• W2979222313 cites W2130514725 @default.
• W2979222313 cites W2148117492 @default.
• W2979222313 cites W2172152967 @default.
• W2979222313 cites W2337386322 @default.
• W2979222313 cites W2465092116 @default.
• W2979222313 cites W2469323349 @default.
• W2979222313 cites W2526220138 @default.
• W2979222313 cites W2592660691 @default.
• W2979222313 cites W2610528373 @default.
• W2979222313 cites W2736966846 @default.
• W2979222313 cites W2745459169 @default.
• W2979222313 cites W2771347394 @default.
• W2979222313 cites W2775321189 @default.
• W2979222313 cites W2783796657 @default.
• W2979222313 cites W2803161119 @default.
• W2979222313 cites W2887423209 @default.
• W2979222313 cites W2896703180 @default.
• W2979222313 cites W4252775619 @default.
• W2979222313 doi "https://doi.org/10.1016/j.ijrobp.2019.09.007" @default.
• W2979222313 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31593756" @default.
• W2979222313 hasPublicationYear "2020" @default.
• W2979222313 type Work @default.
• W2979222313 sameAs 2979222313 @default.
• W2979222313 citedByCount "34" @default.
• W2979222313 countsByYear W29792223132020 @default.
• W2979222313 countsByYear W29792223132021 @default.
• W2979222313 countsByYear W29792223132022 @default.
• W2979222313 countsByYear W29792223132023 @default.
• W2979222313 crossrefType "journal-article" @default.
• W2979222313 hasAuthorship W2979222313A5016754892 @default.
• W2979222313 hasAuthorship W2979222313A5022999007 @default.
• W2979222313 hasAuthorship W2979222313A5041705953 @default.
• W2979222313 hasAuthorship W2979222313A5042610590 @default.
• W2979222313 hasAuthorship W2979222313A5045236213 @default.
• W2979222313 hasAuthorship W2979222313A5068826699 @default.
• W2979222313 hasConcept C119060515 @default.
• W2979222313 hasConcept C121608353 @default.
• W2979222313 hasConcept C126322002 @default.
• W2979222313 hasConcept C126894567 @default.
• W2979222313 hasConcept C141071460 @default.
• W2979222313 hasConcept C155806632 @default.
• W2979222313 hasConcept C168563851 @default.
• W2979222313 hasConcept C203092338 @default.
• W2979222313 hasConcept C2776235491 @default.
• W2979222313 hasConcept C2777899217 @default.
• W2979222313 hasConcept C2779384505 @default.
• W2979222313 hasConcept C2780192828 @default.
• W2979222313 hasConcept C509974204 @default.
• W2979222313 hasConcept C71924100 @default.
• W2979222313 hasConceptScore W2979222313C119060515 @default.
• W2979222313 hasConceptScore W2979222313C121608353 @default.
• W2979222313 hasConceptScore W2979222313C126322002 @default.
• W2979222313 hasConceptScore W2979222313C126894567 @default.
• W2979222313 hasConceptScore W2979222313C141071460 @default.
• W2979222313 hasConceptScore W2979222313C155806632 @default.
• W2979222313 hasConceptScore W2979222313C168563851 @default.
• W2979222313 hasConceptScore W2979222313C203092338 @default.
• W2979222313 hasConceptScore W2979222313C2776235491 @default.
• W2979222313 hasConceptScore W2979222313C2777899217 @default.
• W2979222313 hasConceptScore W2979222313C2779384505 @default.
• W2979222313 hasConceptScore W2979222313C2780192828 @default.
• W2979222313 hasConceptScore W2979222313C509974204 @default.
• W2979222313 hasConceptScore W2979222313C71924100 @default.
• W2979222313 hasFunder F4320322777 @default.
• W2979222313 hasIssue "1" @default.
• W2979222313 hasLocation W29792223131 @default.
• W2979222313 hasLocation W29792223132 @default.
• W2979222313 hasOpenAccess W2979222313 @default.
• W2979222313 hasPrimaryLocation W29792223131 @default.
• W2979222313 hasRelatedWork W2067177021 @default.
• W2979222313 hasRelatedWork W2126365059 @default.
• W2979222313 hasRelatedWork W2487490720 @default.
• W2979222313 hasRelatedWork W2766427323 @default.
• W2979222313 hasRelatedWork W2793077515 @default.
• W2979222313 hasRelatedWork W2980097659 @default.
• W2979222313 hasRelatedWork W2981615369 @default.
• W2979222313 hasRelatedWork W3014461208 @default.

• next